- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
The Globe and Mail reported that Raymond James analyst Alex Terentiew has downgraded North American Palladium Ltd. (TSX:PDL,AMEX:PAL) to “market perform” from “outperform,” while Sam Crittenden, an analyst at RBC Dominion Securities, moved his rating from “sector perform” down to “underperform.”
The Globe and Mail reported that Raymond James analyst Alex Terentiew has downgraded North American Palladium Ltd. (TSX:PDL,AMEX:PAL) to “market perform” from “outperform,” while Sam Crittenden, an analyst at RBC Dominion Securities, moved his rating from “sector perform” down to “underperform.”
As quoted in the market news:
North American Palladium Ltd. only has about one month before it runs out of cash, making it critical for the company to issue new equity immediately, warned Raymond James analyst Alex Terentiew.
“With its chief operating officer departing, an LDI operations review ongoing, and need for financing enhanced due to negative preliminary revisions to 2013 production, cash costs and capex guidance, we believe the pressure falls squarely on the shoulders of the new CEO Phil du Toit to carry the company through this challenging time,” he said in a research note.
Mr. Terentiew slashed his price target to $1.40 from $2.50. Mr. Crittenden cut his target to $1.25 from $1.75.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.